Altitude Training for Runners: Does Live High, Train Low Work?

What is live high, train low, and why split them?

Live high, train low separates two competing demands. Living at moderate altitude exposes the body to reduced oxygen for many hours a day, which is thought to stimulate the kidneys to release erythropoietin and, over weeks, increase red blood cell mass and oxygen-carrying capacity. The problem is that training hard at altitude is difficult: thinner air forces slower paces and lower power, degrading the quality of key sessions. Training low solves this by keeping fast work at or near sea level, where runners can hit genuine race-specific intensities.

Levine and Stray-Gundersen (1997) tested exactly this logic. They randomised 39 competitive runners to live high and train low, live high and train high, or live low and train low for four weeks. Only the group that lived at around 2,500 m but trained at 1,250 m improved 5,000 m performance. The design has shaped altitude practice ever since.

What did the foundational study find?

The Levine and Stray-Gundersen (1997) trial remains the reference point. Over four weeks, the live high, train low group improved their 5,000 m time-trial by roughly 13.4 seconds, about 1.1 percent. This coincided with an increase in red cell mass and a rise in VO2max of around 5 percent. The two comparison groups, living high and training high, or living and training low, showed no equivalent gain.

The interpretation is that the performance benefit came from the hypoxic living dose driving a haematological adaptation, while preserved sea-level training quality allowed that fitness to be expressed in a fast time-trial. It is worth keeping the magnitude in perspective: roughly one percent is meaningful in elite racing but small, and it was measured in already-trained runners over a short block. The study established the mechanism and the method, not a guarantee of large improvement for every athlete who tries it.

Why do some runners respond and others don't?

Averages hide a lot. Chapman, Stray-Gundersen and Levine (1998) reanalysed the LHTL athletes and found striking individual variation. The runners they classed as responders improved their 5,000 m time by around 36 seconds and showed clear rises in erythropoietin, red cell mass and VO2max. Non-responders did not improve, largely because they failed to mount an adequate erythropoietic response to the altitude stimulus.

This established the responder and non-responder concept that still frames altitude coaching. If your body does not raise EPO and build red cells in response to the hypoxic dose, the main proposed mechanism simply does not fire, and performance is unlikely to move. It means altitude is not a uniform intervention: two runners on the identical camp can walk away with very different results. The practical implication is to monitor the response where possible, rather than assume the average benefit applies to you.

Is the benefit real or partly placebo?

This is where the evidence gets genuinely mixed, and it depends on natural versus simulated altitude. Bonetti and Hopkins (2009) pooled six hypoxia protocols and found natural live high, train low produced substantial gains in both elite (around 4.0 percent) and subelite (around 4.2 percent) endurance athletes. Artificial, simulated LHTL helped subelite athletes but showed little likely benefit for elite ones.

The most pointed challenge came from Siebenmann et al. (2012), the first rigorously double-blinded, placebo-controlled LHTL trial. Sixteen cyclists spent four weeks in normobaric hypoxia (around 3,000 m simulated) or a placebo normoxic condition. Haemoglobin mass, VO2max and time-trial power were unchanged in both groups, with no between-group difference. The authors suggested some previously reported benefits from simulated altitude may reflect placebo and expectancy effects. Taken together, natural altitude looks more trustworthy than tents and chambers, and blinding matters.

How high should you live, and for how long?

Dose appears to be decisive. Chapman et al. (2014) had 48 collegiate distance runners live at one of four altitudes and train low for four weeks. The 3,000 m time-trial improved most at living altitudes of roughly 2,000 to 2,500 m. Living higher, at 2,800 m, gave no extra benefit and could impair training quality, defining an optimal living-altitude window.

Daily exposure matters too. Lancaster and Smart (2012), pooling 11 studies, found LHTL athletes had a higher VO2max than normoxic controls, with a much larger gain when protocols supplied at least around 9.5 hours of daily hypoxic exposure. Feng et al. (2023), in a network meta-analysis, ranked LHTL as the most effective hypoxic method for VO2max and described an inverted-U dose response: too little exposure does nothing, and excessively high altitude yields diminishing or negative returns. The takeaway is a moderate altitude, sustained for enough hours across enough weeks.

Does altitude reliably raise VO2max?

Not as cleanly as the mechanism suggests. Lancaster and Smart (2012) reported a significant VO2max advantage for LHTL over normoxic controls, with a weighted mean difference of about 1.51 mL/kg/min, rising to around 3.45 with sufficient daily hypoxic dose. Feng et al. (2023) likewise favoured LHTL for aerobic capacity.

Yet a more recent meta-analysis complicates the picture. Deng et al. (2025) pooled 13 randomised controlled trials in 276 athletes and found altitude training significantly increased haemoglobin (a standardised mean difference of 0.70) but produced no significant overall change in VO2max compared with low-altitude training. Their subgroup analysis suggested live high, train high and blocks longer than three weeks were most effective for aerobic capacity. The honest reading is that a blood adaptation does not automatically translate into a measurable VO2max gain, and the two outcomes can move independently. Expect the effect on VO2max to be small and inconsistent.

What does this mean for everyday runners?

For a competitive runner with access to genuine moderate altitude, the evidence supports natural live high, train low as the most reliable option: aim to live around 2,000 to 2,500 m, train low for quality, and secure enough daily hypoxic hours across at least three to four weeks. Expect a small average benefit, on the order of one percent in the founding trial, not a transformation.

Temper expectations with the caveats. A meaningful share of runners are non-responders (Chapman et al., 1998), simulated altitude is far less convincing than the real thing (Siebenmann et al., 2012), and VO2max gains are inconsistent across meta-analyses (Deng et al., 2025). Iron status underpins any red-cell response, so it is worth checking before a camp. For most recreational runners, consistent sea-level training, sleep and structured intervals will move performance more than a logistically demanding altitude block. Altitude is a marginal tool, best reserved for those already close to their ceiling.

Does live high, train low actually improve running performance?

On balance, yes, but modestly. Levine and Stray-Gundersen (1997) found only the live high, train low group improved 5,000 m time, by about 1.1 percent, and Bonetti and Hopkins (2009) support natural LHTL in a meta-analysis. The benefit is small on average, depends on getting the altitude dose right, and varies substantially between individual runners.

How high should I live for altitude training?

Moderate altitude works best. Chapman et al. (2014) found 3,000 m time-trial performance improved most when runners lived at roughly 2,000 to 2,500 m and trained low. Living higher, around 2,800 m, gave no additional benefit and could impair training quality. Feng et al. (2023) similarly describe an inverted-U dose response, where too high is counterproductive.

Why do some runners not respond to altitude?

Because the main adaptation may not fire. Chapman, Stray-Gundersen and Levine (1998) identified responders and non-responders: non-responders failed to mount an adequate erythropoietin and red cell mass response to altitude, so their performance did not improve. This is a well-documented feature of altitude training, meaning identical camps can produce very different individual outcomes.

Is simulated altitude as good as real altitude?

The evidence is weaker for simulated altitude. Bonetti and Hopkins (2009) found artificial LHTL helped subelite but not elite athletes, and Siebenmann et al. (2012), in a double-blind placebo-controlled trial, found no change in haemoglobin mass, VO2max or time-trial power from normobaric hypoxia. They suggested some prior simulated-altitude benefits may reflect placebo effects.

Does altitude training raise VO2max?

Inconsistently. Lancaster and Smart (2012) found a significant VO2max advantage for LHTL, larger with sufficient daily hypoxic exposure. However, Deng et al. (2025), pooling 13 randomised trials, found altitude raised haemoglobin but produced no significant overall VO2max change. A blood adaptation does not reliably translate into a measurable VO2max gain, so expect a small and variable effect.

How long does an altitude block need to be?

Several weeks, with enough daily exposure. The foundational trials used around four weeks. Lancaster and Smart (2012) found much larger VO2max gains when protocols provided at least about 9.5 hours of daily hypoxic exposure, and Deng et al. (2025) suggested blocks longer than three weeks were most effective for aerobic capacity. Brief or low-exposure stints are unlikely to help.